Skip to main content
Top
Published in: EJNMMI Research 1/2020

Open Access 01-12-2020 | Autopsy | Original research

Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study

Authors: Michael J. Pontecorvo, C. Dirk Keene, Thomas G. Beach, Thomas J. Montine, Anupa K. Arora, Michael D. Devous Sr, Michael Navitsky, Ian Kennedy, Abhinay D. Joshi, Ming Lu, Geidy E. Serrano, Lucia I. Sue, Anthony J. Intorcia, Shannon E. Rose, Angela Wilson, Leanne Hellstern, Natalie Coleman, Matthew Flitter, Patricia Aldea, Adam S. Fleisher, Mark A. Mintun, Andrew Siderowf

Published in: EJNMMI Research | Issue 1/2020

Login to get access

Abstract

Background

The objective of this study was to make a quantitative comparison of flortaucipir PET retention with pathological tau and β-amyloid across a range of brain regions at autopsy.

Methods

Patients with dementia (two with clinical diagnosis of AD, one undetermined), nearing the end of life, underwent 20-min PET, beginning 80 min after an injection of ~370 mBq flortaucipir [18F]. Neocortical, basal ganglia, and limbic tissue samples were obtained bilaterally from 19 regions at autopsy and subject-specific PET regions of interest corresponding to the 19 sampled target tissue regions in each hemisphere were hand drawn on the PET images. SUVr values were calculated for each region using a cerebellar reference region. Abnormally phosphorylated tau (Ptau) and amyloid-β (Aβ) tissue concentrations were measured for each tissue region with an antibody capture assay (Histelide) using AT8 and H31L21 antibodies respectively.

Results

The imaging-to-autopsy interval ranged from 4–29 days. All three subjects had intermediate to high levels of AD neuropathologic change at autopsy. Mean cortical SUVr averaged across all three subjects correlated significantly with the Ptau immunoassay (Pearson r = 0.81; p < 0.0001). When Ptau and Aβ1-42 were both included in the model, the Ptau correlation with flortaucipir SUVr was preserved but there was no correlation of Aβ1-42 with flortaucipir. There was also a modest correlation between limbic (hippocampal/entorhinal and amygdala) flortaucipir SUVr and Ptau (Pearson r = 0.52; p < 0.080). There was no significant correlation between SUVr and Ptau in basal ganglia.

Conclusions

The results of this pilot study support a quantitative relationship between cortical flortaucipir SUVr values and quantitative measures of Ptau at autopsy. Additional research including more cases is needed to confirm the generalizability of these results.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer’s disease pathology and cerebral infarctions. Neurology. 2005;64:834–41.CrossRef Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer’s disease pathology and cerebral infarctions. Neurology. 2005;64:834–41.CrossRef
2.
go back to reference Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62:1087–95.CrossRef Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62:1087–95.CrossRef
3.
go back to reference Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J Neuropathol Exp Neurol. 2007;66:1136–46.CrossRefPubMedPubMedCentral Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J Neuropathol Exp Neurol. 2007;66:1136–46.CrossRefPubMedPubMedCentral
4.
go back to reference Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropath Exp Neurol. 2009;68:1–14.CrossRef Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropath Exp Neurol. 2009;68:1–14.CrossRef
5.
go back to reference Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362–81.CrossRefPubMedPubMedCentral Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362–81.CrossRefPubMedPubMedCentral
6.
go back to reference Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci. 1970;11:205–42.CrossRef Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci. 1970;11:205–42.CrossRef
7.
go back to reference Mungas D, Tractenberg R, Schneider JA, Crane PK, Bennett DA. A two-process model for neuropathology of Alzheimer’s disease. Neurobiol Aging. 2014;35:301–8.CrossRef Mungas D, Tractenberg R, Schneider JA, Crane PK, Bennett DA. A two-process model for neuropathology of Alzheimer’s disease. Neurobiol Aging. 2014;35:301–8.CrossRef
8.
go back to reference Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–78.CrossRefPubMed Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–78.CrossRefPubMed
9.
go back to reference Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287–94.CrossRefPubMed Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287–94.CrossRefPubMed
10.
go back to reference Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study. Alzheimers Dement. 2015;11:964–74.CrossRefPubMed Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study. Alzheimers Dement. 2015;11:964–74.CrossRefPubMed
11.
go back to reference Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand MK-6240 in humans from Alzheimer’s disease dementia to young controls. bioRxiv. March 28, 2018. https://doi.org/10.1101/290064. Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand MK-6240 in humans from Alzheimer’s disease dementia to young controls. bioRxiv. March 28, 2018. https://​doi.​org/​10.​1101/​290064.
12.
go back to reference Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38:171–84.CrossRef Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38:171–84.CrossRef
13.
go back to reference Declercq L, Rombouts F, Koole M, Fierens K, Mariën J, Langlois X, et al. Preclinical evaluation of 18F-JNJ64349311, a novel pet tracer for tau imaging. J Nucl Med. 2017;58:975–81.CrossRef Declercq L, Rombouts F, Koole M, Fierens K, Mariën J, Langlois X, et al. Preclinical evaluation of 18F-JNJ64349311, a novel pet tracer for tau imaging. J Nucl Med. 2017;58:975–81.CrossRef
14.
go back to reference Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med. 2016;57:208–14.CrossRef Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med. 2016;57:208–14.CrossRef
15.
go back to reference Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094–108.CrossRef Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094–108.CrossRef
16.
go back to reference Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer’s disease. J Nuc Med. 2013;54:1420–7.CrossRef Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer’s disease. J Nuc Med. 2013;54:1420–7.CrossRef
18.
go back to reference Villemagne VL, Dore V, Bourgeat P, Burnham SC, Laws S, Salvado O, et al. Aβ-amyloid and tau imaging in dementia. Semin Nucl Med. 2017;47:75–88.CrossRef Villemagne VL, Dore V, Bourgeat P, Burnham SC, Laws S, Salvado O, et al. Aβ-amyloid and tau imaging in dementia. Semin Nucl Med. 2017;47:75–88.CrossRef
19.
go back to reference Wong DF, Comley R, Kuwabara H, Rosenberg PB, Resnick SM, Ostrowitzki S, et al. Characterization of 3 novel tau radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in healthy controls and in Alzheimer subjects. J Nucl Med. 2018;59:1869–76.CrossRefPubMedPubMedCentral Wong DF, Comley R, Kuwabara H, Rosenberg PB, Resnick SM, Ostrowitzki S, et al. Characterization of 3 novel tau radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in healthy controls and in Alzheimer subjects. J Nucl Med. 2018;59:1869–76.CrossRefPubMedPubMedCentral
20.
go back to reference Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9:666–76.CrossRef Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9:666–76.CrossRef
21.
go back to reference Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389–404.CrossRefPubMedPubMedCentral Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389–404.CrossRefPubMedPubMedCentral
23.
go back to reference Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer’s disease spectrum. Ann Neurol. 2016;80:247–58.CrossRef Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer’s disease spectrum. Ann Neurol. 2016;80:247–58.CrossRef
24.
go back to reference Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79:110–9.CrossRef Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79:110–9.CrossRef
25.
26.
go back to reference Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, et al. Relationships between flortaucipir (18F-AV-1451) positron emission tomography tau binding and amyloid burden clinical diagnosis, age and cognition. Brain. 2017;140:748–63.PubMedPubMedCentral Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, et al. Relationships between flortaucipir (18F-AV-1451) positron emission tomography tau binding and amyloid burden clinical diagnosis, age and cognition. Brain. 2017;140:748–63.PubMedPubMedCentral
27.
go back to reference Schöll M, Lockhart SN, Schonhaut DR, O'Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89:971–82.CrossRefPubMedPubMedCentral Schöll M, Lockhart SN, Schonhaut DR, O'Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89:971–82.CrossRefPubMedPubMedCentral
28.
go back to reference Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139:1539–50.CrossRef Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139:1539–50.CrossRef
29.
go back to reference Josephs KA, Whitwell JL, Tacik P, Duffy JR, Senjem ML, Tosakulwong N, et al. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy confirmed corticobasal degeneration. Acta Neuropathol. 2016;132:931–3.CrossRefPubMedPubMedCentral Josephs KA, Whitwell JL, Tacik P, Duffy JR, Senjem ML, Tosakulwong N, et al. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy confirmed corticobasal degeneration. Acta Neuropathol. 2016;132:931–3.CrossRefPubMedPubMedCentral
30.
go back to reference Marquié M, Normandin MD, Meltzer AC, Siao tick Chong M, Andrea NV, Antón-Fernández A, et al. Pathologic correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies. Ann Neurol. 2017;81:117–28.CrossRefPubMedPubMedCentral Marquié M, Normandin MD, Meltzer AC, Siao tick Chong M, Andrea NV, Antón-Fernández A, et al. Pathologic correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies. Ann Neurol. 2017;81:117–28.CrossRefPubMedPubMedCentral
32.
go back to reference McMillan CT, Irwin DJ, Nasrallah I, Phillips JS, Spindler M, Rascovsky K, et al. Multimodal evaluation demonstrates in vivo18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016;132:935–7.CrossRefPubMedPubMedCentral McMillan CT, Irwin DJ, Nasrallah I, Phillips JS, Spindler M, Rascovsky K, et al. Multimodal evaluation demonstrates in vivo18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016;132:935–7.CrossRefPubMedPubMedCentral
33.
go back to reference Smith R, Puschmann A, Schöll M, Ohlsson T, van Swieten J, Honer M, et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain. 2016;139:2372–9.CrossRefPubMedPubMedCentral Smith R, Puschmann A, Schöll M, Ohlsson T, van Swieten J, Honer M, et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain. 2016;139:2372–9.CrossRefPubMedPubMedCentral
34.
go back to reference Smith R, Scholl M, Honer M, Nilsson CF, Englund E, Hansson O. Tau neuropathology correlates with FDG-PET but not AV-1451-PET in progressive supranuclear palsy. Acta Neuropathol. 2017;133:149–51.CrossRef Smith R, Scholl M, Honer M, Nilsson CF, Englund E, Hansson O. Tau neuropathology correlates with FDG-PET but not AV-1451-PET in progressive supranuclear palsy. Acta Neuropathol. 2017;133:149–51.CrossRef
36.
go back to reference Smith R, Wilbom M, Pawlik D, Englund E, Hansson O. Correlation of in vivo [18F]flortaucipir with postmortem Alzheimer disease tau pathology. JAMA Neurol. 2019;76:310–7.CrossRef Smith R, Wilbom M, Pawlik D, Englund E, Hansson O. Correlation of in vivo [18F]flortaucipir with postmortem Alzheimer disease tau pathology. JAMA Neurol. 2019;76:310–7.CrossRef
37.
go back to reference Postupna N, Rose SE, Bird TD, Gonzalez-Cuyar LF, Sonnen JA, Larson EB, et al. Novel antibody capture assay for paraffin-embedded tissue detects wide-ranging amyloid beta and paired helical filament-tau accumulation in cognitively normal older adults. Brain Pathol. 2012;22:472–84.CrossRef Postupna N, Rose SE, Bird TD, Gonzalez-Cuyar LF, Sonnen JA, Larson EB, et al. Novel antibody capture assay for paraffin-embedded tissue detects wide-ranging amyloid beta and paired helical filament-tau accumulation in cognitively normal older adults. Brain Pathol. 2012;22:472–84.CrossRef
38.
go back to reference Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8:1–13.CrossRefPubMedPubMedCentral Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8:1–13.CrossRefPubMedPubMedCentral
39.
go back to reference Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging - Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123:1–11.CrossRef Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging - Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123:1–11.CrossRef
40.
go back to reference Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.CrossRef Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.CrossRef
42.
go back to reference Shcherbinin S, Schwarz AJ, Joshi AJ, Navitsky M, Flitter M, Shankle WR, et al. Kinetics of the tau PET tracer [18F]-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment and Alzheimer’s disease. J Nuc Med. 2016;10:1535–42.CrossRef Shcherbinin S, Schwarz AJ, Joshi AJ, Navitsky M, Flitter M, Shankle WR, et al. Kinetics of the tau PET tracer [18F]-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment and Alzheimer’s disease. J Nuc Med. 2016;10:1535–42.CrossRef
43.
go back to reference Bevan Jones WR, Cope TE, Passamonti L, Fryer TD, Hong YT, Aigbirhio F, et al. [18FAV-1451] PET in behavioral variant frontal temporal dementia due to MAPT mutation. Ann Clin Trans Neurol. 2016;3:940–7.CrossRef Bevan Jones WR, Cope TE, Passamonti L, Fryer TD, Hong YT, Aigbirhio F, et al. [18FAV-1451] PET in behavioral variant frontal temporal dementia due to MAPT mutation. Ann Clin Trans Neurol. 2016;3:940–7.CrossRef
44.
go back to reference Postupna N, Keene CD, Crane PK, Gonzalez-Cuyar LF, Sonnen JA, Hewitt J, et al. Cerebral cortical Aβ42 and PHF-τ in 325 consecutive brain autopsies varies by diagnosis, location, and APOE. J Neuropathol Exp Neurol. 2015;74:100–9.CrossRefPubMedPubMedCentral Postupna N, Keene CD, Crane PK, Gonzalez-Cuyar LF, Sonnen JA, Hewitt J, et al. Cerebral cortical Aβ42 and PHF-τ in 325 consecutive brain autopsies varies by diagnosis, location, and APOE. J Neuropathol Exp Neurol. 2015;74:100–9.CrossRefPubMedPubMedCentral
45.
go back to reference Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787–800.CrossRefPubMedPubMedCentral Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787–800.CrossRefPubMedPubMedCentral
46.
go back to reference Vermeiren C, Motte P, Viot D, Mairet-Coello G, Courade JP, Citron M, et al. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord. 2018;33:273–81.CrossRef Vermeiren C, Motte P, Viot D, Mairet-Coello G, Courade JP, Citron M, et al. The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord. 2018;33:273–81.CrossRef
48.
go back to reference Wright J, Lin YG, Goodman J, Lieberman B, Clemens J, Hoye A, et al. Studies to evaluate the putative binding of the tau positron emission tomography tracer 18F-AV-1451 to monoamine oxidase-B (MAO-B). Alzheimer’s association international conference, Los Angeles, CA 2019. Alzheimers Dementia. 2019;15:75–2 131.CrossRef Wright J, Lin YG, Goodman J, Lieberman B, Clemens J, Hoye A, et al. Studies to evaluate the putative binding of the tau positron emission tomography tracer 18F-AV-1451 to monoamine oxidase-B (MAO-B). Alzheimer’s association international conference, Los Angeles, CA 2019. Alzheimers Dementia. 2019;15:75–2 131.CrossRef
49.
go back to reference Hansen AK, Brooks DJ, Borghammer P. MAO-B inhibitors do not block in vivo flortaucipir([(18)F]-AV-1451) binding. Mol Imaging Biol. 2018;20:356–60.CrossRef Hansen AK, Brooks DJ, Borghammer P. MAO-B inhibitors do not block in vivo flortaucipir([(18)F]-AV-1451) binding. Mol Imaging Biol. 2018;20:356–60.CrossRef
Metadata
Title
Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study
Authors
Michael J. Pontecorvo
C. Dirk Keene
Thomas G. Beach
Thomas J. Montine
Anupa K. Arora
Michael D. Devous Sr
Michael Navitsky
Ian Kennedy
Abhinay D. Joshi
Ming Lu
Geidy E. Serrano
Lucia I. Sue
Anthony J. Intorcia
Shannon E. Rose
Angela Wilson
Leanne Hellstern
Natalie Coleman
Matthew Flitter
Patricia Aldea
Adam S. Fleisher
Mark A. Mintun
Andrew Siderowf
Publication date
01-12-2020
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2020
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-020-00653-x

Other articles of this Issue 1/2020

EJNMMI Research 1/2020 Go to the issue